Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Lonza Group AG
  6. News
  7. Summary
    LONN   CH0013841017

LONZA GROUP AG

(LONN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna sees no impact on COVID-19 vaccine from potential patent waiver

05/06/2021 | 11:24am EDT
FILE PHOTO: SOMOS Community Care administers Moderna COVID-19 Vaccine at pop-up site in New York

(Reuters) - Moderna Inc on Thursday said it believes countries around the globe would continue buying its COVID-19 vaccine for years even if patents on the shots are waived, noting that rivals would face significant hurdles in scaling up manufacturing.

The comments come a day after the United States said it would support waiving intellectual property rights for COVID-19 vaccines in order to help speed an end to the pandemic, paving the way for what could be months of negotiations to hammer out a specific waiver plan.

Moderna shares were off 7.5% after falling as much as nearly 12% earlier. Shares of other COVID-19 vaccine manufacturers like Pfizer Inc were also down on the patent news.

"While this is a negative headline," said Morgan Stanley analysts in a research note, there is no mechanism "to force management to teach other manufacturers how to make their vaccine, suggesting no change to the status quo."

Moderna, which said in October it would not enforce patents on its vaccine during the pandemic, noted the lack of companies able to rapidly scale up complex manufacturing of a similar vaccine to meet surging global demand.

"They will have to go run a clinical trial, get the data, get the product approved and scale manufacturing. This does not happen in 6 or 12 or 18 months," Moderna Chief Executive Stephane Bancel said on a post-earnings conference call.

Moderna has faced its own hurdles scaling up production with some shortfalls in the manufacturing supply chain, which includes Swiss contract manufacturer Lonza Group, leading to delivery delays in Europe.

Bancel said he has had to tell some countries, "we're very sorry. We have no more supply for you in 2021."

Still, the company said it expects to produce between 800 million to 1 billion doses this year.

Moderna raised its 2021 sales forecast for its COVID-19 shot by 4.3% to $19.2 billion on Thursday, two days after Pfizer increased its full-year COVID-19 vaccine sales forecast more than 70% to $26 billion.

Moderna expects vaccine output could increase to 3 billion doses in 2022 to meet demand from nations looking to stock up supplies and sign up deals for "booster" doses.

Early clinical trial data released on Wednesday showed that a third dose of either Moderna's current shot or an experimental new vaccine increases immunity against the more easily transmissible virus variants first found in Brazil and South Africa.

Moderna, which is seeking to expand authorization of its vaccine to children and adolescents, on Thursday said an initial analysis of a study in those aged 12 to 17 showed an efficacy rate of 96%.

The company also reported its first-ever quarterly profit on sales of the vaccine.

(Reporting by Manas Mishra in Bengaluru and Carl O'Donnell in New York; Editing by Arun Koyyur and Bill Berkrot)

By Manas Mishra and Carl O'Donnell


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
DOW JONES AFRICA TITANS 50 INDEX -0.10% 531.45 Delayed Quote.-0.26%
DOW JONES SOUTH AFRICA(ZAR) 0.05% 1896.58 Delayed Quote.6.93%
EURO / BRAZILIAN REAL (EUR/BRL) 0.13% 5.8696 Delayed Quote.-6.55%
LONZA GROUP AG -0.66% 659.8 Delayed Quote.16.70%
MODERNA, INC. 3.82% 220.14 Delayed Quote.110.72%
MORGAN STANLEY 1.41% 87.08 Delayed Quote.27.07%
PFIZER, INC. 0.36% 39.19 Delayed Quote.6.47%
S&P AFRICA 40 INDEX 0.15% 171.44 Delayed Quote.-1.34%
All news about LONZA GROUP AG
06/24LONZA  : to Manufacture Pinteon Therapeutics' Antibody For Alzheimer's, Traumati..
MT
06/24LONZA  : Pinteon Extends Collaboration with Lonza for Manufacturing PNT001, a No..
PU
06/24LONZA  : CellPoint Team Up To Manufacture CAR-T Cell Therapies For Cancer Treatm..
MT
06/23LONZA  : CellPoint and Lonza to Leverage the Cocoon Platform for T-Cell Therapeu..
PU
06/23LONZA  : Headline
PU
06/22LONZA  : European Commission OKs Bain, Cinven's Acquisition of Lonza's Specialty..
MT
06/21LONZA  : SelectImmune Pharma Seek to Develop Immunotherapeutic Drug
MT
06/21LONZA  : SelectImmune Collaborates with Lonza to Develop an Immunotherapeutic Dr..
PU
06/21LONZA  : SelectImmune Pharma Collaborates with Lonza to Develop an Immunotherape..
AQ
06/20LONZA  : to Develop, Manufacture ValenzaBio's Antibody For Autoimmune Diseases
MT
More news
Financials
Sales 2021 5 053 M 5 510 M 5 510 M
Net income 2021 835 M 910 M 910 M
Net Debt 2021 1 197 M 1 305 M 1 305 M
P/E ratio 2021 58,5x
Yield 2021 0,47%
Capitalization 49 309 M 53 670 M 53 769 M
EV / Sales 2021 9,99x
EV / Sales 2022 9,04x
Nbr of Employees 16 540
Free-Float 99,6%
Chart LONZA GROUP AG
Duration : Period :
Lonza Group AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LONZA GROUP AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 663,80 CHF
Average target price 685,14 CHF
Spread / Average Target 3,21%
EPS Revisions
Managers and Directors
Pierre-Alain Ruffieux Chief Executive Officer
Rodolfo Savitzky Chief Financial Officer
Albert M. Baehny Chairman
Werner J. Bauer Independent Director
Barbara May Richmond No-Executive Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
LONZA GROUP AG16.70%53 670
MODERNA, INC.102.97%85 140
IQVIA HOLDINGS INC.35.24%46 441
CELLTRION, INC.-22.42%33 893
SEAGEN INC.-10.43%28 470
PHARMARON BEIJING CO., LTD.73.47%25 331